Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
10
05
2023
medline:
8
6
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Non-small cell lung cancer (NSCLC) is the predominant histological subtype of lung cancer and is the leading cause of cancer-related deaths globally. Quality of life is an important consideration for patients and current treatments can adversely affect health-related quality of life (HRQoL). The objectives of this systematic literature review (SLR) were to identify and provide a comprehensive catalogue of published health state utility values (HSUVs) in patients with early-stage NSCLC and to understand the factors impacting on HSUVs in this indication. Electronic searches of Embase, MEDLINE and Evidence-Based Medicine Reviews were conducted via the Ovid platform in March 2021 and June 2022 and were supplemented by grey literature searches of conference proceedings, reference lists, health technology assessment bodies, and other relevant sources. Eligibility criteria were based on patients with early-stage (stage I-III) resectable NSCLC receiving treatment in the adjuvant or neoadjuvant setting. No restriction was placed on interventions or comparators, geography, or publication date. English language publications or non-English language publications with an English abstract were of primary interest. A validated checklist was applied to conduct quality assessment of the full publications. Twenty-nine publications (27 full publications and two conference abstracts) met all eligibility criteria and reported 217 HSUVs and seven disutilities associated with patients with early NSCLC. The data showed that increasing disease stage is associated with decreasing HRQoL. It was also indicated that utility values vary by treatment approach; however, the choice of treatment may be influenced by the patients' disease stage at presentation. Few studies aligned with the requirements of health technology assessment (HTA) bodies, indicating a need for future studies to conform to these preferences, making them suitable for use in economic evaluations. This SLR found that disease stage and treatment approach were two of several factors that can impact patient-reported HRQoL. Additional studies are warranted to confirm these findings and to investigate emerging therapies for early NSCLC. In collecting a catalogue of HSUV data, this SLR has begun to identify the challenges associated with identifying reliable utility value estimates suitable for use in economic evaluations of early NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Non-small cell lung cancer (NSCLC) is the predominant histological subtype of lung cancer and is the leading cause of cancer-related deaths globally. Quality of life is an important consideration for patients and current treatments can adversely affect health-related quality of life (HRQoL).
OBJECTIVE
OBJECTIVE
The objectives of this systematic literature review (SLR) were to identify and provide a comprehensive catalogue of published health state utility values (HSUVs) in patients with early-stage NSCLC and to understand the factors impacting on HSUVs in this indication.
METHODS
METHODS
Electronic searches of Embase, MEDLINE and Evidence-Based Medicine Reviews were conducted via the Ovid platform in March 2021 and June 2022 and were supplemented by grey literature searches of conference proceedings, reference lists, health technology assessment bodies, and other relevant sources. Eligibility criteria were based on patients with early-stage (stage I-III) resectable NSCLC receiving treatment in the adjuvant or neoadjuvant setting. No restriction was placed on interventions or comparators, geography, or publication date. English language publications or non-English language publications with an English abstract were of primary interest. A validated checklist was applied to conduct quality assessment of the full publications.
RESULTS
RESULTS
Twenty-nine publications (27 full publications and two conference abstracts) met all eligibility criteria and reported 217 HSUVs and seven disutilities associated with patients with early NSCLC. The data showed that increasing disease stage is associated with decreasing HRQoL. It was also indicated that utility values vary by treatment approach; however, the choice of treatment may be influenced by the patients' disease stage at presentation. Few studies aligned with the requirements of health technology assessment (HTA) bodies, indicating a need for future studies to conform to these preferences, making them suitable for use in economic evaluations.
CONCLUSIONS
CONCLUSIONS
This SLR found that disease stage and treatment approach were two of several factors that can impact patient-reported HRQoL. Additional studies are warranted to confirm these findings and to investigate emerging therapies for early NSCLC. In collecting a catalogue of HSUV data, this SLR has begun to identify the challenges associated with identifying reliable utility value estimates suitable for use in economic evaluations of early NSCLC.
Identifiants
pubmed: 37289325
doi: 10.1007/s41669-023-00423-0
pii: 10.1007/s41669-023-00423-0
pmc: PMC10471534
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
723-738Informations de copyright
© 2023. The Author(s).
Références
Thorax. 2010 Oct;65(10):903-7
pubmed: 20861294
Patient. 2017 Feb;10(1):105-115
pubmed: 27567613
J Geriatr Oncol. 2021 Jan;12(1):102-105
pubmed: 32535014
J Thorac Oncol. 2018 May;13(5):689-698
pubmed: 29391288
Signal Transduct Target Ther. 2019 Dec 17;4:61
pubmed: 31871778
MDM Policy Pract. 2018 Oct 15;3(2):2381468318801565
pubmed: 30349874
Lung Cancer. 2006 Aug;53(2):217-29
pubmed: 16765475
Health Qual Life Outcomes. 2016 Apr 12;14:60
pubmed: 27072351
Lung Cancer. 2018 Oct;124:298-309
pubmed: 29961557
Chest. 2013 May;143(5 Suppl):e278S-e313S
pubmed: 23649443
J Thorac Oncol. 2010 Dec;5(12):1953-7
pubmed: 21155140
Pharmacoeconomics. 2023 Feb;41(2):199-207
pubmed: 36449173
Lung Cancer. 2010 Dec;70(3):347-51
pubmed: 20395012
Med Decis Making. 2015 Apr;35(3):371-87
pubmed: 25670839
BMC Cancer. 2018 Nov 8;18(1):1081
pubmed: 30409116
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
J Clin Oncol. 2008 Nov 1;26(31):5052-9
pubmed: 18809617
Radiother Oncol. 2020 Mar;144:65-71
pubmed: 31733490
Health Technol Assess. 2012;16(18):1-75, iii-iv
pubmed: 22472180
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Ann Am Thorac Soc. 2020 Aug;17(8):988-997
pubmed: 32433897
Clin Lung Cancer. 2019 Sep;20(5):378-383
pubmed: 31202692
Eur J Cardiothorac Surg. 2019 Oct 01;56(4):754-761
pubmed: 30838382
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2009 Sep 10;27(26):4268-73
pubmed: 19667274
Gen Thorac Cardiovasc Surg. 2019 Dec;67(12):1056-1061
pubmed: 31098867
J Clin Oncol. 2022 Apr 1;40(10):1127-1129
pubmed: 35167335
Transl Lung Cancer Res. 2019 Aug;8(4):332-339
pubmed: 31555509
Pharmacoeconomics. 2020 Nov;38(11):1187-1200
pubmed: 32754857
J Geriatr Oncol. 2018 Nov;9(6):575-582
pubmed: 29871849
Ann Oncol. 2021 Dec;32(12):1637-1642
pubmed: 34481037
J Thorac Oncol. 2019 Nov;14(11):1892-1900
pubmed: 31352073
Lung Cancer. 2022 Aug;170:34-40
pubmed: 35700630
Pharmacoeconomics. 2001;19(8):855-63
pubmed: 11596837
N Engl J Med. 2014 Nov 6;371(19):1793-802
pubmed: 25372087
Lung Cancer. 2014 Oct;86(1):96-101
pubmed: 25178685
Integr Cancer Ther. 2018 Dec;17(4):1095-1102
pubmed: 30136589
Sci Rep. 2017 Oct 19;7(1):13543
pubmed: 29051570